Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

Abstract: The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to sorafenib is unfortunately common. In this review, we briefly describe systemic therapies that can be considered for patients with HCC who show resistance or intolerance to sorafenib. For all patients with HCC who need systemic therapy, we strongly advocate for participation in clinical trials. Cytotoxic chemotherapy plays a minor role in the treatment of advanced HCC, with some data supporting the use of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) and GEMOX (gemcitabine-oxaliplatin). Multi-target kinase inhibitors such as lenvatinib and regorafenib have recently met their primary endpoints as first- and second-line therapy, respectively, with regorafenib now representing the only FDA-approved drug for second-line treatment of HCC. Other targeted therapies remain under investigation, but results so far have not significantly changed clinical practice. Immunotherapy is an interesting area of research in the treatment of HCC with preclinical and early clinical data demonstrating exciting results; thus numerous investigational studies are currently focusing on immunotherapy in the treatment of HCC. While systemic treatment options in HCC remain a challenge for providers, in this review, we summarize the current literature and highlight areas of progress with respect to the treatment of patients with HCC and resistance or intolerance to sorafenib.

Keywords: liver cancer, chemotherapy, immunotherapy

Introduction

Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in the US and around the world. The incidence of HCC is increasing, with an estimated 782,000 new cases per year worldwide.\(^1\) In the US, where there are approximately 4 million people living with chronic infection of hepatitis C virus (HCV) and where the annual incidence rate of HCC among patients with HCV-related cirrhosis is 2%–8%, we can expect an increase in the annual incidence rate of HCC despite effective HCV treatment.\(^2,3\) In addition, recent data have shown that metabolic disorders, such as nonalcoholic fatty liver disease (NAFLD), account for more number of cases of HCC than any other risk factor including HCV infection, which is primarily due to the high prevalence of NAFLD in the overall population.\(^4\) Sixty to seventy percent of the patients present with advanced disease which is not appropriate for surgical resection or liver-directed therapies.\(^5\) Therefore, for such patients, systemic therapy is highly recommended.\(^6\)
The only US FDA-approved first-line systemic therapy for HCC is sorafenib, which is a multi-targeted oral small molecule tyrosine kinase inhibitor (TKI) that inhibits Raf kinase, the vascular endothelial growth factor receptors (VEGFRs) 1–3 and the platelet-derived growth factor receptor-β (PDGFR-β). Sorafenib was approved on the basis of results from the Phase III SHARP trial which demonstrated an overall survival (OS) benefit of sorafenib compared with best supportive care alone (10.7 months versus 7.9 months; hazard ratio [HR]=0.69; 95% confidence interval [CI]=0.55–0.87; \( P<0.001 \)). The most common severe sorafenib-related toxicity was found to be diarrhea (grade 3 in 8% of the patients; grade 4 in <1% of the patients), hand–foot syndrome (grade 3 in 8% of the patients), and fatigue (grade 3 in 8% of the patients; grade 4 in 1% of the patients). Most frequent reasons for discontinuation of sorafenib were found to be gastrointestinal events (6%), fatigue (5%), and liver dysfunction (5%).

Despite the observed survival benefit from sorafenib, resistance to sorafenib is very common. Primary resistance to sorafenib was identified in about a quarter of patients in the SHARP trial; however, 43% of the patients’ disease was found to be in control, which lasted for more days (≥28 days) beyond the first scan showing response or stable disease. Resistance to sorafenib is thought to be mediated overexpression of epidermal growth factor receptor (EGFR) by the tumor including other downstream signaling molecules. Acquired resistance to sorafenib involves several mechanisms, such as abnormal activation of PI3K/Akt and JAK-STAT pathways, the activation of hypoxia-inducible pathways to allow progression of malignant cells despite hypoxia, and epithelial–mesenchymal transition which enhances tumor cell migration and invasion.

While many patients with sorafenib intolerance or resistance are unable to receive additional therapy because of the advanced nature of their disease and cirrhosis, those with a good performance status often seek additional options. Because of comorbid cirrhosis and the general chemotherapy-refractory nature of HCC, finding second and third line treatment options can be challenging. Herein, we will describe systemic therapies that can be considered in patients with sorafenib refractory HCC. A summary of agents studied for use in HCC is provided in Table 1, with the most promising therapeutic options and their outcomes shown in Table 2.

### Clinical trials

Given the generally dismal outcomes in HCC, patients with HCC who are not candidates for resection or transplantation should be considered for clinical trials whenever possible. There is a growing understanding of the signaling pathways that drive hepatic carcinogenesis, and their components represent potential molecular targets for therapy in HCC (Table 3). Somatic genomic profiling using multiplex assays may be a

### Table 1 Therapeutic agents studied for treatment of advanced hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Cytotoxic chemotherapy</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF)</td>
<td>Doxorubicin</td>
<td>Fluorouracil/leucovorin/oxaliplatin (FOLFOX)</td>
</tr>
<tr>
<td>Gemcitabine/oxaliplatin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hormone therapies</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Luteinizing hormone</td>
<td>Megestrol</td>
<td>Octreotide</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Molecularly targeted therapies</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TKi, tyrosine kinase inhibitor.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Multi-targeted agents</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lenvatinib</td>
<td>Regorafenib</td>
<td>Sorafenib</td>
</tr>
</tbody>
</table>

| TKi, tyrosine kinase inhibitor. |

<table>
<thead>
<tr>
<th>Mesenchymal–epithelial transition factor (MET) inhibitors</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tivantinib</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anti-vascular endothelial growth factor (VEGF) agents</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Axitinib</td>
<td>Bevacizumab</td>
<td>Ramucirumab</td>
</tr>
<tr>
<td>Sunitinib</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anti-epidermal growth factor receptor (EGFR) agents</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetuximab</td>
<td>Erlotinib</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other targeted therapies</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Everolimus (mTOR inhibitor)</td>
<td>Brivanib (fibroblast growth factor receptor TKI)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2 Therapeutic options for first- and second-line treatment of advanced hepatocellular carcinoma

<table>
<thead>
<tr>
<th>First-line therapy</th>
<th>Median PFS (months)</th>
<th>Median OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib²⁸</td>
<td>3.7</td>
<td>12.3</td>
</tr>
<tr>
<td>Lenvatinib²⁹</td>
<td>7.4</td>
<td>13.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second-line therapy</th>
<th>Median PFS (months)</th>
<th>Median OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regorafenib³⁰</td>
<td>3.1</td>
<td>10.6</td>
</tr>
<tr>
<td>FOLFOX³¹</td>
<td>2.9</td>
<td>Not met in study</td>
</tr>
<tr>
<td>GemOx³²</td>
<td>5</td>
<td>12</td>
</tr>
</tbody>
</table>

**Abbreviations:** OS, overall survival; PFS, progression-free survival.

(eg, Ras/Raf/MAPK, WNT-β-catenin, EGFR, insulin-like growth factor receptor, AKT-mTOR, Notch, and Hedgehog)
Table 3 Phase II and III studies of targeted therapies in hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Agent(s) studied</th>
<th>Mechanism of action of agent studied</th>
<th>Year published</th>
<th>Primary endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib versus placebo</td>
<td>Multi-targeted TKI, VEGFR inhibitor</td>
<td>2008</td>
<td>Overall survival</td>
<td>10.7 versus 7.9 months (P&lt;0.001)</td>
</tr>
<tr>
<td>Sorafenib versus sorafenib</td>
<td>Multi-targeted TKI, VEGFR inhibitor</td>
<td>2013</td>
<td>Overall survival for futility and safety reasons</td>
<td>7.9 versus 10.2 months (P=0.0014)</td>
</tr>
<tr>
<td>Sorafenib versus erlotinib versus sorafenib</td>
<td>EGFR TKI</td>
<td>2015</td>
<td>Overall survival</td>
<td>9.5 versus 9.9 months (HR=1.06; 95% CI=0.93–1.22)</td>
</tr>
<tr>
<td>Linifanib versus sorafenib</td>
<td>VEGFR and PDGFR TKI</td>
<td>2015</td>
<td>Overall survival</td>
<td>9.1 versus 9.8 months (HR=0.92; 95% CI=0.896–1.221)</td>
</tr>
<tr>
<td>Lenvatinib versus sorafenib</td>
<td>Multi-targeted TKI</td>
<td>2017</td>
<td>Overall survival, noninferiority</td>
<td>13.6 versus 12.3 months (HR=0.92, 95% CI=0.79–1.06)</td>
</tr>
<tr>
<td>Brivanib versus placebo</td>
<td>VEGFR and FGFR inhibitor</td>
<td>2012</td>
<td>Overall survival</td>
<td>9.4 versus 8.2 months (P=0.3307)</td>
</tr>
<tr>
<td>Ramucirumab versus placebo</td>
<td>VEGFR inhibitor, monoclonal antibody</td>
<td>2015</td>
<td>Overall survival</td>
<td>9.2 versus 7.6 months (P=0.14)</td>
</tr>
<tr>
<td>Tivantinib versus placebo</td>
<td>MET inhibitor</td>
<td>2017</td>
<td>Overall survival</td>
<td>8.4 versus 9.1 months (P=0.81)</td>
</tr>
<tr>
<td>Regorafenib versus placebo</td>
<td>Multi-targeted TKI</td>
<td>2017</td>
<td>Overall survival</td>
<td>10.6 versus 7.8 months (P&lt;0.0001)</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>PD-1 immune checkpoint inhibitor</td>
<td>2017</td>
<td>Objective response rate</td>
<td>20% (95% CI=0.15–26)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; MET, mesenchymal–epithelial transition factor; PD-1, programmed cell death-1; PDGFR, platelet-derived growth factor receptor; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.

way to enrich clinical care by detecting actionable mutations, though the percentage of patients with HCC with actionable mutations in a recent prospective clinical sequencing study was less than 10%.10 Creating tools to match patients with actionable mutations with available clinical trials is an area of ongoing investigation, and the number of “actionable” mutations is expected to increase as basic and clinical sciences increasingly focus on precision oncology.11 For all of our patients with HCC who need systemic therapy, we strongly advocate for participation in clinical trials.

Cytotoxic chemotherapy

Cytotoxic chemotherapy plays a minor role in the treatment of advanced HCC. Doxorubicin was long considered the most effective chemotherapeutic agent in the treatment of advanced HCC, but recent evidence refutes any significant benefit. Alliance/CALGB 80802 compared sorafenib alone to sorafenib in combination with doxorubicin in 346 patients with advanced HCC. Patients treated with combination therapy experienced more toxicity and inferior OS (9.3 months vs 10.5 months for sorafenib) or progression-free survival (PFS).12 A randomized Phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) showed modest overall improvements in overall response rate and median survival with PIAF. However, the results were not statistically significant, and treatment-related toxicity was observed in patients receiving PIAF.13 Somewhat more promising data support the use of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) and GEMOX (gemcitabine-oxaliplatin). A Phase III trial involving 371 Asian patients with advanced HCC comparing modified FOLFOX and doxorubicin (50 mg/m² every 3 weeks) showed improved PFS for FOLFOX (2.93 months vs 1.77 months; HR=0.79; 95% CI=0.63–0.99; P<0.001). The primary endpoint of difference in OS was not met, but there was a trend toward improvement with FOLFOX (HR=0.79; 95% CI=0.63–0.99; P=0.04). Proportions of grade 3 or 4 adverse events were similar between treatment groups.14 It is unclear whether these findings in patients with predominantly hepatitis B virus (HBV)-associated HCC can be extrapolated to American patients with predominantly HCV- and NAFLD-associated HCC.

A number of small, single arm trials suggest that GEMOX is a good option for advanced HCC. In a study, 21 patients with advanced HCC demonstrated an overall response rate of 19% (95% CI=13%–26%), median PFS of 5 months, and median OS of 12 months.15 In another study, in 32 patients with previously untreated advanced HCC, GEMOX produced
a response rate of 18% (95% CI=8%–34%), median PFS of 6.3 months, and OS of 11.5 months. For unclear reasons, treatment was significantly more effective in patients with nonalcoholic rather than alcoholic cirrhosis.16 In both trials, GEMOX was reasonably well tolerated.

A meta-analysis of 13 studies using first-line oxaliplatin-based chemotherapy demonstrated a pooled response rate of 16.8%. The median PFS and OS were found to be 4.2 and 9.3 months, respectively, and the 1-year OS was 37%.17 As the majority of data on chemotherapy in HCC is from the first-line setting, there is substantial uncertainty regarding the tolerability of such an approach following sorafenib failure. However, for medically fit patients who have progressed on sorafenib and regorafenib and who are unable to participate in a clinical trial, we recommend the use of FOLFOX or GEMOX.

**Hormone therapies**

Several hormonal agents studied in HCC, including tamoxifen, megestrol, octreotide, and lanreotide, have failed to show meaningful clinical benefit in HCC. Due to the presence of estrogen receptors on one-third of HCCs, estrogen receptor blockade with tamoxifen was hypothesized to have potential benefit in HCC. Four randomized controlled trials (RCTs) and a Cochrane systematic review of tamoxifen in HCC failed to show improvement with respect to survival or functional status.18–22 Data are conflicting regarding the use of megestrol in HCC. A small RCT comparing megestrol versus supportive care alone showed improved median OS with megestrol (18 months, 95% CI=13.47–22.53 months) versus untreated patients (7 months, 95% CI=3.01–10.99, P=0.0090).23 However, a larger randomized placebo-controlled trial involving 204 patients with treatment-naive advanced HCC showed no improvement in OS, and in fact showed worse outcomes amongst patients with poor performance status or Child Pugh class B or C who received megestrol.24 Somatostatin analogs, such as octreotide and lanreotide, have been studied in HCC and have shown some survival benefit in patients with positive octreotide scans25 but have failed to show consistent improvement with respect to PFS or OS.26–30 The balance of evidence suggests that hormone therapies are not effective against HCC and should not be considered part of clinical practice.

**Molecularly targeted therapies**

Since sorafenib’s approval, there have been multiple trials comparing first-line sorafenib to a novel targeted agent or combined with another agent that have failed to show any clinically relevant benefit over sorafenib.12,31–33 A variety of drugs have also failed to show benefit in the second-line setting.34–37 The two key exceptions are lenvatinib and regorafenib, both multi-target TKIs that have recently met their primary endpoints in first- and second-line therapy, respectively.

**Multi-targeted agents**

Regorafenib is an orally active nonspecific TKI that works by inhibiting several pro-neoplastic pathways, including those involved in angiogenesis, growth, and metastasis. In April 2017, the FDA approved regorafenib for second-line use in patients with HCC who were previously treated with sorafenib on the basis of the RESORCE trial, a randomized double-blind placebo controlled trial of the efficacy of regorafenib in advanced, refractory HCC.38,39 This study of 573 patients with ECOG PS 0-1 and Child Pugh A cirrhosis whose tumors had progressed after receiving sorafenib demonstrated a median OS of 10.6 months with regorafenib versus 7.8 months with placebo (HR=0.63; 95% CI=0.50–0.79; one-sided P<0.0001). The median PFS was found to be 3.1 months with regorafenib versus 1.5 months with placebo. The profile of clinically relevant adverse events were as expected from regorafenib including hypertension (15% in regorafenib group versus 5% in placebo group), hand–foot syndrome (13% versus 1%), fatigue (9% versus 5%), and diarrhea (3% versus 0%). The recommended dose of regorafenib is 160 mg once daily on days 1–21 of a 28-day cycle.39 This is the first new FDA-approved drug for HCC in more than a decade and represents the only FDA-approved drug for second-line treatment of HCC.

Lenvatinib, another oral multikinase inhibitor that targets VEGFR, FGFR, PDGFR-beta, RET, and KIT, demonstrated similar activity as sorafenib as a first-line treatment for advanced HCC.40 In the open-label REFLECT study, 954 patients with untreated HCC were randomized to receive lenvatinib or sorafenib as initial therapy. The trial met its primary endpoint, showing lenvatinib to be noninferior to sorafenib (median OS 13.6 vs 12.3 months, HR=0.92, 95% CI=0.79–1.06). Median PFS was better in lenvatinib-treated patients (7.4 months vs 3.7 months, HR=0.66, 95% CI=0.57–0.77), as was the disease control rate of 71.7% versus 60.5%. Lenvatinib did not, however, have a better adverse effect profile. Patients reported similar declines in health-related quality of life after treatment initiation in both groups and similar rates of severe toxicities.40

**Hepatocyte growth factor/MET inhibitors**

The mesenchymal–epithelial transition (MET) factor receptor is dysregulated in HCC. Tivantinib is a selective oral MET
inhibitor with a tolerable safety profile that demonstrated initial efficacy against HCC in tumors with high MET expression.\textsuperscript{32,41} Unfortunately, in the randomized, placebo-controlled METIV-HCC Phase III trial, tivantinib did not improve PFS or OS as second-line therapy for patients with MET high HCC.\textsuperscript{42}

**Anti-VEGF therapies**

Given the highly vascular nature of HCC and high levels of VEGF expression, multiple other agents that target the VEGF pathway have been evaluated in HCC. These agents consistently demonstrate some clinical activity, but fewer patients seem to derive benefit from drugs targeting VEGF alone compared to VEGF pathway inhibitors used in combination with other targets.

Bevacizumab, an anti-VEGF monoclonal antibody, has shown activity as a single agent and in combination with other drugs in HCC. A small Phase II study of bevacizumab in 46 patients with liver-confined HCC, good performance status and compensated liver disease demonstrated a PFS of 65% at 6 months and objective response in six patients (13%; 95% CI=3%–23%). Median PFS time was found to be 6.9 months (95% CI, 6.5–9.1 months), and OS was found to be 53% at 1 year, 28% at 2 years, and 23% at 3 years. The most commonly recorded clinically significant adverse events included hypertension, thrombosis, and hemorrhage, including one fatal variceal bleed.\textsuperscript{43}

Bevacizumab has also been studied in combination with other therapies. A small Phase II trial combining bevacizumab with GEMOX showed a median OS of 9.6 months and median PFS of 5.3 months. The most common treatment-related grade 3 to 4 toxicities recorded were leukopenia/neutropenia, transient elevation of aminotransferases, hypertension, and fatigue.\textsuperscript{44} While this study demonstrated the safety and efficacy of the combination of bevacizumab and GEMOX, it is unclear whether the combination is better than bevacizumab or GEMOX given alone. Another Phase II trial combining bevacizumab with oxaliplatin and capecitabine showed a median PFS of 6.8 months and median OS of 9.8 months. Eight patients (20%) achieved partial response and 23 patients (58%) had stable disease, conferring an overall disease control rate of 77.5%. The combination therapy was generally well tolerated with limited grade 3/4 toxicity recorded; the toxicities were mainly peripheral neurotoxicity and fatigue.\textsuperscript{45} A Phase II study of bevacizumab with erlotinib showed a median time to progression of 3.9 months and median OS of 9.9 months.\textsuperscript{46} The consensus of the National Comprehensive Cancer Network (NCCN) at this time is that there are insufficient data to support the use of bevacizumab in patients with HCC.\textsuperscript{6}

Sunitinib, another nonspecific TKI which targets the VEGFRs amongst other pathways, failed to show significant efficacy in HCC. A large, randomized Phase III study comparing sunitinib and sorafenib was terminated early for futility and safety reasons.\textsuperscript{31} Axitinib, a second-generation TKI that targets VEGFRs, has been studied in a randomized Phase II trial of patients with advanced HCC with progression or intolerance of sorafenib. This study compared best supportive care plus axitinib versus placebo, and found no significant difference in median OS.\textsuperscript{47}

Ramucirumab is a recombinant monoclonal antibody that inhibits the VEGFR. A Phase III trial of patients previously treated with sorafenib failed to show significant improvement in OS over placebo (9.2 versus 7.6 months; HR=0.87, 95% CI=0.72–1.05; \(P=0.14\)), but it did show improvement in median PFS (2.8 versus 2.1 months; HR=0.63, 95% CI=0.52–0.75; \(P<0.001\)) and time to tumor progression (3.5 versus 2.6 months; HR=0.59; 95% CI=0.49–0.72; \(P<0.001\)). Unplanned subset analysis suggested the potential for a survival benefit in patients with a high initial level of alpha-fetoprotein (AFP, \(>400 \text{ ng/mL}\)) at diagnosis,\textsuperscript{42} and a follow-up Phase III study among patients with elevated baseline AFP is currently underway (NCT02435433).

**Anti-EGFR therapies**

Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in HCC; however, neither EGFR TKIs nor monoclonal antibodies have demonstrated benefit against HCC. Erlotinib, an oral TKI with specificity for EGFR, offers some modest control over HCC as demonstrated in two Phase II studies investigating first-line use of the drug.\textsuperscript{58,49} Its efficacy in combination with bevacizumab has been studied with conflicting results.\textsuperscript{30,51} In an ongoing randomized Phase II trial, investigators are studying how bevacizumab in combination in comparison to sorafenib as the first-line therapy (NCT00881751). Erlotinib combined with sorafenib was assessed in a randomized Phase III trial and showed no significant improvement in OS compared to sorafenib with placebo. In addition, in patients receiving erlotinib and sorafenib, the disease control rate was significantly lower (43.9% versus 52.5%; \(P=0.021\)).\textsuperscript{33}

When studied in a Phase II trial, cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, was generally well tolerated but showed no antitumor activity in HCC.\textsuperscript{52} Cetuximab has been combined with capecitabine and
oxaliplatin

33 and GEMOX

34 in single arm Phase II trials with disappointing results.

Other targeted therapies

The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and angiogenesis, and the mTOR pathway is activated in 40%–50% of the patients with HCC.

55 Based on early promise in the Phase II setting, everolimus (an mTOR inhibitor) was studied in a large Phase III trial of patients with progression or intolerance to sorafenib. This study showed no improvement in OS over placebo.

36 Fibroblast growth factor (FGF) proteins are involved in tumor growth and angiogenesis in HCC and are thought to play a role in relapse with sorafenib through evasion of VEGF blockade. Brivanib is a selective dual inhibitor of FGF and VEGF receptor tyrosine kinases. The Phase III BRISK-PS trial evaluated the efficacy and safety of brivanib in patients with advanced HCC who had intolerance to or progression on or after sorafenib. Brivanib did not significantly improve median OS compared to placebo (9.4 versus 8.2 months, HR=0.89; 95.8% CI=0.69–1.15; P=0.3307).

35 Other studies are underway to determine whether FGF receptor inhibitors have greater efficacy in selected patients with FGF amplification (NCT02421185, NCT02508467, and NCT03144661).

Immunotherapy

Without a doubt, immuno-oncology is the most exciting new therapeutic arena in HCC. There is a substantial body of evidence that supports the rationale for the use of immune-based approaches to treat HCC.

56 This theoretical rationale is now supported by evidence that multiple checkpoint inhibitors are active in advanced HCC.

Some of the earliest data on immunotherapy came from a Phase II study of the CTLA-4 inhibitor tremelimumab in patients with chronic HCV and advanced HCC. In this small study, tremelimumab resulted in a response rate of 18%, a disease control rate of 76%, and a median OS of 8.2 months.

37 More recently, the large Phase I/II CheckMate 040 study of nivolumab, a human monoclonal antibody inhibitor of programmed death-1 (PD-1), has shown that nivolumab has robust activity in advanced HCC. This study included 262 patients with unselected PD-L1 tumors—both treatment naïve patients and those who had received one prior line of therapy, usually sorafenib. Following confirmation of safety and tolerability in the dose-escalation phase, all patients in the dose-expansion phase received intravenous nivolumab 3 mg/kg every 2 weeks until disease progression or limiting toxicity. The overall objective response rate was 15% (95% CI=6–28) in the dose-escalation phase, including three complete responses and four partial responses, and 20% (95% CI=15–26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase. Notably, responses were observed regardless of PD-L1 expression on tumor cells, and typically occurred within 3 months of treatment initiation. Median OS was found to be 28.8 months in the sorafenib naïve group, and 15.6 months in the sorafenib-treated group.

58 The most common grade 3 or 4 treatment-related adverse events consisted of increased levels of aspartate aminotransferase (4%) and alanine aminotransferase (2%), without any evidence of clinical repercussions. Symptomatic treatment-related adverse events were comparable in patients with and without viral hepatitis infection.

59 The Phase III CheckMate 459 trial is currently underway and aims to compare nivolumab and sorafenib as first-line therapy in patients with advanced HCC (NCT02576509).

In addition to nivolumab, multiple other immune checkpoint inhibitors are being evaluated in HCC. For example, durvalumab (anti-PDL1) has shown comparable response rates and duration of disease control as nivolumab in a small Phase I/II trial.

59 The Phase III KEYNOTE-240 study is an ongoing randomized, double blind, placebo controlled study of pembrolizumab versus placebo in patients with sorafenib refractory/intolerance advanced HCC (NCT02702401). Combination CTLA-4 and PD-1/PDL-1 inhibitor trials are also ongoing with durvalumab/tremelimumab (NCT02519348) as well as nivolumab/ipilimumab (CheckMate 040, NCT01658878).

Challenges and opportunities for treatment of HCC

HCC remains one of the leading causes of cancer-related deaths around the world, and there is an unmet need for systemic therapies to effectively and safely treat patients with this cancer. While we are beginning to see some promise of improved therapeutic options (summarized in Table 2), a great need for further investigation exists. We strongly encourage all patients with advanced HCC to participate in clinical trials. The complexity of this disease underscores the importance of a multidisciplinary clinical approach and a multi-faceted research approach encompassing clinical providers, clinical and basic science researchers, and public health leaders. While optimal therapy for second-line treatment of HCC remains unclear, we anticipate promising
therapies on the horizon that will only be possible through the willing participation of both patients and providers in investigation of new therapies.

Disclosure
The authors report no conflicts of interest in this work.

References


